Harpoon Therapeutics to Present Preclinical Data on its TriTAC-XR Platform at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
05 oct. 2021 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in Three Upcoming Virtual Investor Conferences
02 sept. 2021 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
05 août 2021 16h05 HE
|
Harpoon Therapeutics
Presented updated interim Phase 1/2a clinical trial data for PSMA-targeting TriTAC® HPN424 in prostate cancer at ASCO Annual Meeting Provided clinical trial updates for three additional TriTAC...
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
03 août 2021 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform
04 juin 2021 16h00 HE
|
Harpoon Therapeutics
Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life...
Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC® HPN424 at the 2021 ASCO Annual Meeting
04 juin 2021 09h00 HE
|
Harpoon Therapeutics
The ongoing dose escalation Phase 1/2a trial has enrolled 89 patients with progressive, metastatic castration-resistant prostate cancer in 13 cohorts.Safety data continues to show that HPN424 is...
Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual Meeting
19 mai 2021 17h02 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced...
Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
06 mai 2021 16h04 HE
|
Harpoon Therapeutics
Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs Appointed experienced biotech leader Alan Colowick, M.D., to board of directors ...
Harpoon Therapeutics to Participate in Truist Securities Life Sciences Summit
28 avr. 2021 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021
10 avr. 2021 08h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...